Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
. The authors recommend further efforts to evaluate the indirect costs associated with CRC screening that were not considered in this study. Source of funding Funded in part by Grants-in-Aid for Scientific Research (No. 09670384) from the Ministry of Education and Science and Culture of Japan and Cancer Research (No. 8-2) from the Ministry of Health and Welfare of Japan. Bibliographic details Nakama H, Zhang B, Fukazawa K. Colorectalcancer screening under the age of 50 is less cost-effective. GICancer (...) 2001; 3(5): 371-374 Other publications of related interest Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectalcancer with faecal-occult-blood test. Lancet 1996;348:1467-71. Hardcastle JD, Chamberlain JO, Robinson MH, Moss SM, Amar SS, Balfour TW, et al. Randomised controlled trial of faecal-occult-blood screening for colorectalcancer. Lancet 1996;348:1472-6. Lieberman DA. Cost-effectiveness model for coloncancer screening. Gastroenterology
in average risk adults. In: Young GP, et al., (eds). Prevention and early detection of colorectalcancer. Philadelphia: WB Saunders; 1996. p. 321-56. Winawer SJ, et al. Colorectalcancer screening: clinical guidelines and rationale. Gastroenterology 1997;112:594-642. Indexing Status Subject indexing assigned by NLM MeSH Anti-Inflammatory Agents, Non-Steroidal /economics /therapeutic use; Aspirin /economics /therapeutic use; Colonoscopy /economics; ColorectalNeoplasms /epidemiology /prevention & Cost (...) Aspirin as an adjunct to screening for prevention of sporadic colorectalcancer: a cost-effectiveness analysis Aspirin as an adjunct to screening for prevention of sporadic colorectalcancer: a cost-effectiveness analysis Aspirin as an adjunct to screening for prevention of sporadic colorectalcancer: a cost-effectiveness analysis Ladabaum U, Chopra C L, Huang G, Scheiman J M, Chernew M E, Fendrick A M Record Status This is a critical abstract of an economic evaluation that meets the criteria
Value and cost of follow-up after adjuvant treatment of patients with Dukes' C coloniccancer Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.
Cost-effectiveness of colorectalcancer screening Cost-effectiveness of colorectalcancer screening Cost-effectiveness of colorectalcancer screening McMahon P M, Bosch J L, Gleason S, Halpern E F, Lester J S, Gazelle G S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Four strategies for the screening of colorectalcancer (CRC) were analysed: colonoscopy (CSCPY), double-contrast barium enema examination (DCBE), faecal occult blood testing (FOBT), and flexible sigmoidoscopy (FS). All of these are widely used in current practice. Type of intervention Screening. Economic study type Cost-effectiveness analysis. Study population The characteristics of the patient population studied were unclear. It seemed that the patient population
Park K C, Schwimmer J, Shepherd J E, Phelps M E, Czernin J R, Schiepers C, Gambhir S S. Decision analysis for the cost-effective management of recurrent colorectalcancer. Annals of Surgery 2001; 233(3): 310-319 PubMedID Other publications of related interest Comment: Annals of Surgery 2001;233:320-1. Indexing Status Subject indexing assigned by NLM MeSH ColorectalNeoplasms /economics /mortality /pathology; Cost-Benefit Analysis; Decision Trees; Direct Service Costs; Fluorodeoxyglucose F18; Humans (...) Decision analysis for the cost-effective management of recurrent colorectalcancer Decision analysis for the cost-effective management of recurrent colorectalcancer Decision analysis for the cost-effective management of recurrent colorectalcancer Park K C, Schwimmer J, Shepherd J E, Phelps M E, Czernin J R, Schiepers C, Gambhir S S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary
changed. Findings by SBU Alert This is a translation of version 1, published on February 2, 2000. The latest version of this report is not available in English. People with a hereditary disposition for colorectalcancer are at high risk for developing cancer during their lifetime. Methods are available both to determine whether such a predisposition exists and to detect early stages of cancer. Given this information, patients can be screened via regular examination of the colon (coloscopy) and in some (...) and prophylactic colectomy in patients with heriditary non-polyposis colorectalcancer mutations. Ann Intern Med 1998;15:787-796. Vasen HF, van Ballegooijen M, Kleibeuker JK, Taal BG, Griffioen G, Nagengast FM et al. A cost-effectiveness analysis of colorectal screening of hereditary non-polyposis colorectalcarcinoma gene carriers. Cancer 1998;82:1632-37. SBU Assessment presents a comprehensive, systematic assessment of available scientific evidence. The certainty of the evidence for each finding
Corticosteroids for the resolution of malignantbowel obstruction in advanced gynaecological and gastrointestinalcancer. Gastrointestinal and ovarian cancers are common cancers. The incidence of associated malignantbowel obstruction in patients with advanced cancers of these types is not known, and the best management of these patients is controversial. Inappropriate management may result in uncontrolled (faeculant) vomiting, pain and distress. Management of the symptoms can include (...) of corticosteroids.A comprehensive list of all studies was provided by an extensive search of the electronic databases, relevant journals, reference lists, the grey literature, contact with investigators and other search strategies outlined in the methods.As the review concentrates on the 'best evidence' available of the role of corticosteroids in malignantbowel obstruction due to advanced gynaecological and gastrointestinalcancer the inclusion criteria were kept fairly broad so as to include all studies
Surgery for the resolution of symptoms in malignantbowel obstruction in advanced gynaecological and gastrointestinalcancer. Intestinal obstruction commonly occurs in progressive advanced gynaecological and gastrointestinalcancers. Management of these patients is difficult due to the patients deteriorating mobility and function (performance status), the lack of further chemotherapeutic options and the high mortality and morbidity associated with palliative surgery. There are marked variations (...) scientific studies on intestinal obstruction due to advanced gynaecological and gastrointestinalcancer, in order to assess the efficacy of surgery.A comprehensive list of studies was provided by an extensive search of electronic databases, relevant journals, bibliographic databases, conference proceedings, reference lists, the grey literature, personal contact and the world wide web.As the review concentrates on the 'best evidence' available of the role of surgery in malignantbowel obstruction
Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Some epidemiological studies have suggested that high dietary intake of calcium and fibre reduces colorectal carcinogenesis. Available data are not sufficient to serve as a basis for firm dietary advice. We undertook a multicentre randomised trial to test the effect of diet supplementation with calcium and fibre on adenoma (...) recurrence.We randomly assigned 665 patients with a history of colorectal adenomas to three treatment groups, in a parallel design: calcium gluconolactate and carbonate (2 g elemental calcium daily), fibre (3.5 g ispaghula husk), or placebo. Participants had colonoscopy after 3 years of follow-up. The primary endpoint was adenoma recurrence. Analyses were by intention to treat.23 patients died, 15 were lost to follow-up, 45 refused repeat colonoscopy, and five developed severe contraindications
2000LancetControlled trial quality: predicted high
The effect of fecal occult-blood screening on the incidence of colorectalcancer. Both annual testing for fecal occult blood and biennial testing significantly reduce mortality from colorectalcancer. However, the effect of screening on the incidence of colorectalcancer remains uncertain, despite the diagnosis and removal of precancerous lesions in many persons who undergo screening.We followed the participants in the Minnesota ColonCancer Control Study for 18 years. A total of 46,551 people (...) between 1986 and 1992. Study participants have been followed with respect to newly diagnosed cases of colorectalcancer and deaths. Follow-up has been more than 90 percent complete.During the 18-year follow-up period, we identified 1359 new cases of colorectalcancer: 417 in the annual-screening group, 435 in the biennial-screening group, and 507 in the control group. The cumulative incidence ratios for colorectalcancer in the screening groups as compared with the control group were 0.80 (95 percent
Management of upper gastro-intestinalcancers Management of upper gastro-intestinalcancers Management of upper gastro-intestinalcancers NHS Centre for Reviews and Dissemination Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHS Centre for Reviews and Dissemination. Management of upper gastro-intestinalcancers. University of York (...) . Effective Health Care 6(4). 2000 Authors' objectives This bulletin aims to summarise the available evidence on the management of upper gastro-intestinalcancers. Authors' conclusions Most people with cancer of the upper gastro-intestinal system survive for only a few months after diagnosis. Long-term (five-year) survival rates for England and Wales for oesophageal, stomach and pancreatic cancer are 9%, 12%, and 3% respectively. These survival rates are generally worse than those reported by other
with open colectomy. 2. To assess the laparoscopic treatment of colorectalmalignancies in relation to long-term survival rates and the risk of tumor implantation in the laparoscopic port sites. Authors' conclusions The ASERNIP-S review group recommended a classification of 2: 'The safety and/or efficacy of the procedure cannot be determined at present due to an evidence base of incomplete and/or poor quality. Further research should be conducted to establish safety and/or efficacy'. Project page URL (...) A systematic review of laparoscopic-assisted resection of colorectalmalignancies A systematic review of laparoscopic-assisted resection of colorectalmalignancies A systematic review of laparoscopic-assisted resection of colorectalmalignancies Australian Safety and Efficacy Register of New Interventional Procedures - Surgical Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has
Guidance on the use of laparoscopic surgery for colorectalcancer Guidance on the use of laparoscopic surgery for colorectalcancer Guidance on the use of laparoscopic surgery for colorectalcancer National Institute for Clinical Excellence Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation National Institute for Clinical Excellence. Guidance on the use (...) of laparoscopic surgery for colorectalcancer. London: National Institute for Clinical Excellence (NICE). Technology Appraisal Guidance 17. 2000 Authors' objectives To provide guidance on the use of laparoscopic surgery for colorectalcancer. Authors' conclusions Guidance 1.1 For colorectalcancer, open rather than laparoscopic resection should be the preferred surgical procedure. 1.2 Laparoscopic surgery should only be undertaken for colorectalcancer as part of a randomised controlled clinical trial
information on the possible justification for introducing screening for colorectalcancer in Finland. This report aims to present the facts in sufficient amount and detail for health policy decisions. Authors' conclusions Like in other industrialised countries, in Finland colorectalcancer is an important cause of premature death. The disease can be detected in symptomless persons at an early, localised stage, when it often is possible to give curative treatment. Screening aims at reducing mortality (...) . Screening for colorectalcancer is being considered in many European countries, but no country at present offers screening for its population. Active follow-up of risk groups takes place in several countries, including Finland; the extent of these programmes varies. Many alternative methods are available for screening. Detection of occult blood in stools is the most common primary test. If blood is detected, the next examination can be either endoscopy or radiography of the colon. Colonoscopy has been
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectalcancer: a multicentre randomised trial. Irinotecan is active against colorectalcancer in patients whose disease is refractory to fluorouracil. We investigated the efficacy of these two agents combined for first-line treatment of metastatic colorectalcancer.387 patients previously untreated with chemotherapy (other than adjuvant) for advanced colorectalcancer were randomly (...) , reversible, non-cumulative, and manageable.Irinotecan combined with fluorouracil and calcium folinate was well-tolerated and increased response rate, time to progression, and survival, with a later deterioration in quality of life. This combination should be considered as a reference first-line treatment for metastatic colorectalcancer.
Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix ColonCancer Prevention Physicians' Network. The risks of colorectalcancer and adenoma, the precursor lesion, are believed to be influenced by dietary factors. Epidemiologic evidence that cereal fiber protects against colorectalcancer is equivocal. We conducted a randomized trial to determine whether dietary supplementation with wheat-bran fiber reduces the rate of recurrence of colorectal (...) adenomas.We randomly assigned 1429 men and women who were 40 to 80 years of age and who had had one or more histologically confirmed colorectal adenomas removed within three months before recruitment began to a supervised program of dietary supplementation with either high amounts (13.5 g per day) or low amounts (2 g per day) of wheat-bran fiber. The primary end point was the presence or absence of new adenomas at the time of follow-up colonoscopy. Subjects and physicians, including colonoscopists, were
Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectalcancer: a randomised trial. QUASAR Collaborative Group. Standard adjuvant chemotherapy for colorectalcancer consists of fluorouracil with folinic acid or levamisole. The large QUASAR randomised trial aimed to investigate (in a two x two design) whether use of a higher dose of folinic acid or addition of levamisole to fluorouracil and folinic acid improved (...) survival.Patients with colorectalcancer, without evident residual disease, were randomly assigned fluorouracil (370 mg/m2) with high-dose (175 mg) or low-dose (25 mg) L-folinic acid and either active or placebo levamisole. The fluorouracil and folinic acid could be given either as six 5-day courses with 4 weeks between the start of the courses or as 30 once-weekly doses. Levamisole (50 mg) or placebo was given three times daily for 3 days repeated every 2 weeks for 12 courses. The primary endpoint
2000LancetControlled trial quality: predicted high
Irinotecan plus fluorouracil and leucovorin for metastatic colorectalcancer. Irinotecan Study Group. The combination of fluorouracil and leucovorin has until recently been standard therapy for metastatic colorectalcancer. Irinotecan prolongs survival in patients with colorectalcancer that is refractory to treatment with fluorouracil and leucovorin. In a multicenter trial, we compared a combination of irinotecan, fluorouracil and leucovorin with bolus doses of fluorouracil and leucovorin (...) as first-line therapy for metastatic colorectalcancer. A third group of patients received irinotecan alone.Patients were randomly assigned to receive irinotecan (125 mg per square meter of body-surface area intravenously), fluorouracil (500 mg per square meter as an intravenous bolus), and leucovorin (20 mg per square meter as an intravenous bolus) weekly for four weeks every six weeks; fluorouracil (425 mg per square meter as an intravenous bolus) and leucovorin (20 mg per square meter
for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary The study evaluated the cost-effectiveness of self-expanding metal stents to treat acute left-sided largebowel obstruction in colorectalcarcinoma. The authors concluded that stenting showed reduction in hospital stay and costs, but further analysis was necessary due to small sample size (...) . The level of bias was likely to have been high and scope of the economic analysis limited. However, as indicated by the authors, results are suggestive of stenting being cost-effective and further research is warranted. Type of economic evaluation Cost-effectiveness analysis Study objective The study evaluated the cost-effectiveness of self-expanding metal stents to treat acute left-sided largebowel obstruction in colorectalcarcinoma. Interventions Two interventions were compared: self-expanding metal
Survival benefit of chemotherapy in metastatic colorectalcancer: a meta-analysis of randomized controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.